Cencora, Inc.
COR · Price history
Price at last available close
$324.35
+$16.75 (+5.45%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Cencora, Inc.
Primary reporting period: 2025-09-30 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U. S.
How they make money
Cencora operates as a global pharmaceutical sourcing and distribution services company. It generates revenue primarily by purchasing pharmaceutical products from manufacturers and distributing them to a wide range of healthcare providers, including hospitals, pharmacies, and physician practices, while also providing value-added services such as inventory management, pharmacy automation, and logistics solutions.
Products & services
Pharmaceutical distribution, specialty pharmacy services, animal health products, pharmacy automation, and logistics solutions for healthcare providers and manufacturers.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Period ended 2025-09-30Source
Period ended 2025-09-30Source
Period ended 2025-09-30Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Period ended 2025-09-30Source
Period ended 2025-09-30Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer concentration
Walgreens and Boots together accounted for approximately 25% of revenue, and Evernorth Health Services accounted for approximately 13% of revenue in fiscal 2025. The top 10 customers, including governmental agencies and group purchasing organizations, represented approximately 66% of revenue in fiscal 2025.
Suppliers, materials & equipment
- Pharmaceutical and biotech manufacturers — Manufacturers of pharmaceutical and related products supplied to healthcare providers.Source
Strengths
- Leading position in pharmaceutical distribution and specialty servicesSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Total debt increased 42.3% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
48
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
61
Fair
Financial Strength
41
Business Quality / Moat
62
Management
88
Growth Quality
43
Risk / Durability
89
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
51
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
54/100
Building Historical Record
Model Score 54/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Asset quality scores strongly
- •Recent buyback activity is present
- •M&A headline · Oct 28, 2026
- •M&A headline · Oct 21, 2026
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for COR
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can COR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is COR's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is COR's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of COR's score?
Essential Investment Snapshot
Wall Street Score
48
Opportunity Score
51
Market Cap
$61.89B
P/E Ratio
22.2
EPS
$13.52
52-Week High
$377.54
52-Week Low
$244.82
Beta
0.57
Intrinsic Value
$397.06
Analyst Target
$350.00
Shares Outstanding
195.2M
Total Revenue
$332.77B
Total Debt
$11.72B
Dividend
No current dividend
Liquidation Value / Share
$16.59
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for COR
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Oct 28, 2026
Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Zacks Investment ResearchM&A headline · Oct 21, 2026
Cencora to acquire American Oncology Network in $2.4 billion deal — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
ReutersM&A headline · Oct 21, 2026
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Business WireCommunity Sentiment
0 active · 0 total callsNo personal call yet on COR.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Leading position in pharmaceutical distribution and specialty services.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Distribution industry.
- −Significant customer concentration.
- −Dependence on pharmaceutical manufacturers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
46
Sep 17, 2026
Change
+2.0
points
Current Score
48
Oct 1, 2026
Category Changes
COR increased 2 points because Capital improved by 2 points, Valuation improved by 8.1 points.
Positive Contributors
- + Capital improved by 2 points
- + Valuation improved by 8.1 points
Projected Score
Projected Score
48
Projected Change
-0.4 points
Preliminary comparable-period financial changes suggest decline of approximately 0.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$324.35
Model Intrinsic Value
$397.06
Difference
−$72.71
-18.3% vs IV
Margin of Safety
18.3%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $332.77B | $321.33B | $293.96B | $262.17B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $320.43B | $311.19B | $285.26B | $254.42B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $12.34B | $10.14B | $8.70B | $7.76B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $7.65B | $6.49B | $5.66B | $5.31B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $8.01B | $6.49B | $5.66B | $5.31B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $5.13B | $3.74B | $3.36B | $3.41B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $4.34B | $3.65B | $3.04B | $2.45B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $497.8M | $419.8M | $248.7M | $275.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $3.61B | $2.26B | $2.00B | $2.16B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $967.3M | $690.5M | $484.7M | $428.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $2.62B | $1.55B | $1.51B | $1.75B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $13.52 | $8.02 | $7.60 | $8.62 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 193M | 194M | 199M | 205M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 194M | 195M | 200M | 205M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$84.75B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$3.94
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+42.3%
Cash Change
+23.7%
Margin Change
+0.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, net income margin. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 5.1%. EPS increased 11.9%. Cash increased 23.7%. Total debt increased 42.3%. Net income margin was essentially unchanged.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DistributionNews
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network
Cencora to acquire American Oncology Network in $2.4 billion deal
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
Rumor Mill · COR
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial